Gene panel model predictive of outcome in men at high-risk of systemic progression and death from prostate cancer after radical retropubic prostatectomy

Journal of Clinical Oncology

Volumn 26, Issue 24, 2008, Pages 3930-3936

  Cheville, John C ^a   Karnes, R Jeffrey ^a   Therneau, Terry M ^a   Kosari, Farhad ^a   Munz, Jan Marie ^a   Tillmans, Lori ^a   Basal, Eati ^a   Rangel, Laureano J ^a   Bergstralh, Eric ^a   Kovtun, Irina V ^a   Savci Heijink, C D ^a   Klee, Eric W ^a   Vasmatzis, George ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; ADD2 PROTEIN; ANTINEOPLASTIC AGENT; AROMATIC LEVO AMINO ACID DECARBOXYLASE; BACULOVIRAL IAP REPEAT CONTAINING PROTEIN 5; BLOOD CLOTTING FACTOR 5; CADHERIN; CADHERIN 10; CADHERIN 7; COLLAGEN TYPE 2 ALPHA1; DNA TOPOISOMERASE (ATP HYDROLYSING) A; GRIN3A PROTEIN; HISTONE DEACETYLASE 9; HS2ST1 PROTEIN; KHDRBS3 PROTEIN; MOLECULAR MARKER; NEUROPILIN 1; PKIB PROTEIN; PTPRM PROTEIN; RAB6B PROTEIN; RIBONUCLEOTIDE REDUCTASE M2; SOMATOSTATIN RECEPTOR 1; SYNDECAN 2; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ER81; TRANSCRIPTION FACTOR ERG; TRANSCRIPTION FACTOR ETV4; TRANSMEMBRANE PROTEIN 45B; TRYPTOPHAN 2,3 DIOXYGENASE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANEUPLOIDY; AREA UNDER THE CURVE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER MODEL; CANCER MORTALITY; CANCER PATIENT; CANCER RISK; CANCER STAGING; CASE CONTROL STUDY; COMPARATIVE STUDY; CONTROLLED STUDY; EMBEDDING; FOLLOW UP; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE OVEREXPRESSION; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; LASER CAPTURE MICRODISSECTION; MAJOR CLINICAL STUDY; MALE; MARKER GENE; MICROARRAY ANALYSIS; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PANEL STUDY; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE; PROSTATE CANCER; PROTEIN EXPRESSION; RADICAL RETROPUBIC PROSTATECTOMY; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS; VALIDATION STUDY; COHORT ANALYSIS; DISEASE COURSE; DNA MICROARRAY; GENETIC PREDISPOSITION; GENETICS; PATHOLOGY; PREDICTION AND FORECASTING; PROSTATE TUMOR; PROSTATECTOMY; STATISTICAL MODEL; TREATMENT OUTCOME;

CASE-CONTROL STUDIES; COHORT STUDIES; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MODELS, STATISTICAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROSTATECTOMY; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

EID: 50549085619     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.15.6752     Document Type: Article

References (35)

1. Humphrey PA: Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol 17:292-306, 2004
2. Blute ML, Bergstralh EJ, Iocca A, et al: Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol 165:119-125, 2001
3. Bostwick DG, Grignon DJ, Hammond ME, et al: Prognostic factors in prostate cancer: College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124:995-1000, 2000
4. Epstein JI, Amin M, Boccon-Gibod L, et al: Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens. Scand J Urol Nephrol 216:34-63, 2005 (suppl)
5. Bismar TA, Demichelis F, Riva A, et al: Defining aggressive prostate cancer using a 12-gene model. Neoplasia 8:59-68, 2006
6. Glinsky GV, Glinskii AB, Stephenson AJ, et al: Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 113:913-923, 2004
7. Rubin MA, Bismar TA, Andren O, et al: Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death. Cancer Epidemiol Biomarkers Prev 14:1424-1432, 2005
8. Singh D, Febbo PG, Ross K, et al: Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 1:203-209, 2002
9. Tomlins SA, Rhodes DR, Perner S, et al: Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310:644-648, 2005
10. Demichelis F, Fall K, Perner S, et al: TMPRSS2: ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 26:4596-4599, 2007
11. Macaluso M, Giordano A: TMPRSS2:ERG Gene Fusion: A new genetic marker for prostate cancer progression. Cancer Biol Ther 6:46-47, 2007
12. Kube DM, Savci-Heijink CD, Lamblin A, et al: Optimization of laser capture microdissection and RNA amplification for gene expression profiling of prostate cancer. BMC Molec Biol 8:8-25, 2007
13. Kosari F, Munz JM, Savci-Heijink D, et al: Identification of biomarkers for prostate cancer. Clin Cancer Res 14:1734-1743, 2008
14. Zanetta G, Keeney GL, Cha SS, et al: Flow-cytometric analysis of deoxyribonucleic acid content in advanced ovarian carcinoma: Its importance in long-term survival. Am J Obstet Gynecol 175:1217-1225, 1996
15. Lossos IS, Czerwinski DK, Alizadeh AA, et al: Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 350:1828-1837, 2004
16. Ramaswamy S, Ross KN, Lander ES, et al: A molecular signature of metastasis in primary solid tumors. Nat Genet 33:49-54, 2003
17. van de Vijver MJ, He YD, van't Veer LJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009, 2002
18. Tabach Y, Milyavsky M, Shats I, et al: The promoters of human cell cycle genes integrate signals from two tumor suppressive pathways during cellular transformation. Mol Syst Biol 1:2005.0022, 2005
19. Whitfield ML, George LK, Grant GD, et al: Common markers of proliferation. Nat Rev Cancer 6:99-106, 2006
20. Sebo TJ, Cheville JC, Riehle DL, et al: Perineural invasion and MIB-1 positivity in addition to Gleason score are significant preoperative predictors of progression after radical retropubic prostatectomy for prostate cancer. Am J Surg Pathol 26:431-439, 2002
21. Hughes C, Murphy A, Martin C, et al: Topoisomerase II-alpha expression increases with increasing Gleason score and with hormone insensitivity in prostate carcinoma. J Clin Pathol 59:721-724, 2006
22. Chowdhury AR, Majumder HK: DNA topoisomerases in life and death: Implications in kineto-plastid protozoa. Curr Mol Med 4:711-722, 2004
23. Pienta KJ, Lehr JE: Inhibition of prostate cancer growth by estramustine and etoposide: Evidence for interaction at the nuclear matrix. J Urol 149:1622-1625, 1993
24. Pienta KJ, Redman B, Hussain M, et al: Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol 12:2005-2012, 1994
25. Kantoff PW, Halabi S, Conaway M, et al: Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 17:2506-2513, 1999
26. Tannock IF, Osoba D, Stockler MR, et al: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 14:1756-1764, 1996
27. Kools P, Vanhalst K, Van den Eynde E, et al: The human cadherin-10 gene: Complete coding sequence, predominant expression in the brain, and mapping on chromosome 5p13-14. FEBS Lett 452:328-334, 1999
28. Shimoyama Y, Tsujimoto G, Kitajima M, et al: Identification of three human type-II classic cadherins and frequent heterophilic interactions between different subclasses of type-II classic cadherins. Biochem J 349:159-167, 2000
29. Davies G, Jiang WG, Mason MD: Cell-cell adhesion molecules and signaling intermediates and their role in the invasive potential of prostate cancer cells. J Urol 163:985-992, 2000
30. De Marzo AM, Knudsen B, Chan-Tack K, et al: E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens. Urology 53:707-713, 1999
31. Kallakury BV, Sheehan CE, Winn-Deen E, et al: Decreased expression of catenins (alpha and beta), p120 CTN, and E-cadherin cell adhesion proteins and E-cadherin gene promoter methylation in prostatic adenocarcinomas. Cancer 92:2786-2795, 2001
32. Loric S, Paradis V, Gala JL, et al: Abnormal E-cadherin expression and prostate cell blood dissemination as markers of biological recurrence in cancer. Eur J Cancer 37:1475-1481, 2001
33. Ray ME, Mehra R, Sandler HM, et al: E-cadherin protein expression predicts prostate cancer salvage radiotherapy outcomes. J Urol 176:1409-1414, 2006; discussion 14
34. Rajput AB, Miller MA, De Luca A, et al: Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J Clin Pathol 60:1238-1243, 2007
35. Hermans KG, van Marion R, van Dekken H, et al: TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Cancer Res 66:10658-10663, 2006